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In human cells, three closely related RAS genes, termed HRAS, KRAS, and NRAS,
encode four highly homologous proteins. RAS proteins are small GTPases involved in
a broad spectrum of key molecular and cellular activities, including proliferation and
survival among others. Gain-of-function missense mutations, mostly located at codons
12, 13, and 61, constitutively activate RAS proteins and can be detected in various
types of human cancers. KRAS is the most frequently mutated, followed by NRAS and
HRAS. However, each isoform exhibits distinctive mutation frequency at each codon,
supporting the hypothesis that different RAS mutants may lead to distinct biologic
manifestations. This review is focused on the differences in signaling and phenotype, as
well as on transcriptomics, proteomics, and metabolomics profiles related to individual
RAS-mutated variants. Additionally, association of these mutants with particular targeted
outcomes and rare mutations at additional RAS codons are discussed.
Keywords: RAS mutations, RAS profile, RAS-mutated cancers, treatment responses, RAS-related omics,
GTP/GDP binding, RAS signaling, rare codons
INTRODUCTION
RAS subfamily comprises the ubiquitously expressed human RAS proteins KRAS4A, KRAS4B (the
two KRAS splice variants), HRAS, and NRAS, which are frequently mutated in cancer (1). These
genes encode small GTPases that function as molecular regulators, controlling a broad spectrum of
cellular activities, such as proliferation and cell survival (2).
RAS proteins are considered molecular switches because they cycle between the “on” and “off”
conformations, which are given by the binding of GTP and GDP, respectively (3). The transition
between both states is regulated by two different protein families. The guanine nucleotide exchange
factors (GEFs) promote GDP dissociation and GTP binding while the GTPase-activating proteins
(GAPs) stimulate RAS intrinsic GTPase activity to switch off this signal.
High homology is shared by the three RAS proteins, except for the C-terminus hypervariable
region, which is thought to confer the specific function of each protein (2). It has been reported
that up to one-third of human cancers (4) bears gain-of-function missense mutations (5) that
occur in the protein region that is identical among the four RAS proteins. Forty-four different point
mutations have been described and 99.2% of them are located at codons 12, 13, and 61 (2), but other
non-canonical codons (such as 19, 117, or 146) are also mutated at low frequencies (6). All these
canonical mutations prompt the loss of the intrinsic and/or the GAP-stimulated GTPase activity
of RAS proteins, leading to a constitutively activated form of RAS. However, some non-canonical
mutations, such as for example HRAS A146 mutations, do not impair RAS GTPase activity, but
increase guanine nucleotide exchange.
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Interestingly, the mutated isoform, as well as the codon
position and the amino acid substitution varies among RAS
proteins in human cancers, but the reason remains to be
established (4). Regarding protein variability, KRAS is the most
frequently mutated protein in human cancers, followed by NRAS
and HRAS. Oncogenic alterations in KRAS are more frequent
in patients with pancreatic carcinoma, colorectal tumors and
lung malignancies (5). Mutations in HRAS can be found in
dermatological malignancies and head and neck cancers, while
NRAS mutations are common in melanomas and in some
hematopoietic malignancies (Table 1) (5).
The mutations rates at each codon differ between the RAS
proteins (2). While KRAS is commonly mutated at codon 12
with only few mutations occurring at codon 61, NRASmutations
are most frequently observed at codon 61. In addition, HRAS
mutational rate is similar for both codons 12 and 61, displaying
an intermediatemutational pattern betweenKRAS andNRAS (2).
Each of these codons can be substituted through a single-
nucleotide change resulting in codons 12 and 13 changes
from glycine to alanine, cysteine, aspartic acid, arginine, serine
or valine and codon 61 from glutamine to glutamic acid,
histidine, lysine, leucine, proline or arginine. In KRAS, the
variations at codons 12 and 13, which are the most frequent
mutations associated with this protein, result in G12D and G13D
substitution, respectively. Similarly, the most common mutation
in HRAS is the G12V substitution. As previously mentioned,
NRAS has a mutation bias at codon 61, Q61R replacement at this
position being the most frequent aberration (2).
Considering that RAS mutations are all located in the
homologous amino-acid region, it could be postulated that their
effect on the protein function is equivalent. Nevertheless, studies
have demonstrated that different substitutions in RAS proteins
distinctly modify protein GTPase activity or its affinity for
downstream effectors (6–8). According to these reports, different
RAS mutations may result in distinct biological manifestations.
As this topic is less discussed in the literature, within this review
we focus on the differences among RAS proteins mutations with
respect to their preferential signaling pathways, biochemistry,
specific changes in cellular phenotype, mutations-specific
transcriptomics, proteomics and metabolomics characteristics,
as well as their individual association with patient treatment
outcome and survival.
RAS PROTEINS: FUNCTIONAL AND
LOCALIZATION VARIANCES
RAS proteins were initially believed to be functionally redundant
due to their high homology in structure, biophysical and
biochemical properties (9). Subsequently, accumulating solid
experimental evidence indicated that RAS proteins differ
substantially in their function in various cell types and tissues (9).
For example, while, KRAS4A-, NRAS-, or HRAS-deficient mice
are viable, KRAS4B knockout mice die during embryogenesis
between days 12 and term due to liver, cardiac and hematopoietic
abnormalities (10–13). These findings suggest that only KRAS4B
may be essential during development and that there might be
a redundancy in signaling among the other RAS proteins in
embryogenesis. Later on, Potenza et al. modified the KRAS gene
to encode an HRAS protein, showing that HRAS can functionally
replace KRAS during embryogenesis but only under the control
of KRAS promoter (6). However, these adult mice displayed
dilated cardiomyopathy, indicating that KRAS has a unique
role in cardiovascular homeostasis (14) and that the mortality
of KRAS-deficient mice is likely derived from the inability of
other RAS proteins to be expressed in the same subcellular
compartments (9).
In relation to the protein-specific role of RAS in mouse
embryogenesis, some studies have pointed out also their similar
specific functions in human development. It has been shown that
germline mutations in RAS proteins or in RAS regulators, such as
NF1, PTPN11, or SOS1, lead to several congenital developmental
disorders, such as neurofibromatosis type 1, Noonan, or Costello
syndromes, respectively (9). Therefore, these data in combination
with the aforementioned animal experiments indicate that
normal development is regulated by a precise pattern of RAS
signaling (15).
Numerous mechanistic studies from the last two
decades support the notion that each RAS protein displays
specific downstream signaling (16–20). The distinct protein
functionalities can be attributed to different post-translational
modifications occurring at the C-termini of the RAS proteins.
These modifications allow RAS proteins to anchor in different
subcellular membranes from where each protein can activate
different signaling pathways (21). Although plasma membrane
is the major location for all the RAS proteins, they have also
been found in the endoplasmic reticulum, Golgi apparatus,
endosomal network, and mitochondria (21). Interestingly, the
level of each protein in these subcellular compartments varies
according to their total abundance and between cell types. For
example, Chiu et al. reported that NRAS and HRAS maintain the
highest Golgi pool, followed by KRAS4A and KRAS4B, which
are mainly located in the plasma membrane (18).
Early evidences from plasma membrane perturbation studies
support the idea of compartmentalized RAS protein signaling.
Roy et al. reported that HRAS but not KRAS4B was able to
inhibit RAF/MAPK signaling pathway (16). In addition, analysis
of mutant RAS proteins revealed distinctive RAF1 (CRAF)
activation, with KRAS4B and KRAS4A being more potent RAF1
activators than NRAS or HRAS (17). Moreover, the protein-
specific signaling leads to different outputs depending on the
RAS subcellular localization (15). For example, KRAS anchored
in the plasma membrane can induce cellular transformation,
while its activation when located in the mitochondria triggers
apoptosis (19). In the case of HRAS, Chiu et al. demonstrated
that only the endoplasmic reticulum-associated form can
activate the RAF1-ERK signaling pathway, leading to fibroblast
transformation (18). However, HRAS Golgi-associated form
seems to be unable to induce cell transformation or proliferation
(20). Taken together, these data suggest that RAS protein
subcellular localization modulates signaling pathway activation
and its outcome.
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TABLE 1 | Most common mutations in the individual codons of RAS proteins.
RAS protein Malignancies Codon Amino acid substitution
HRAS Dermatological
Head and neck cancer
Codon 12: GGC (Gly, G) 12A, 12C, 12D, 12R, 12S, 12V
Codon 13: GGT (Gly, G) 13C, 13D, 13R, 13S, 13V
Codon 61: CAG (Gln, Q) 61H, 61K, 61L, 61P, 61R
KRAS Pancreatic carcinoma
Colorectal cancer
Lung malignancies
Codon 12: GGT (Gly, G) 12A, 12C, 12D, 12R, 12S, 12V
Codon 13: GGC (Gly, G) 13A, 13C, 13D, 13R, 13S, 13V
Codon 61: CAA (Gln, Q) 61E, 61H, 61K, 61L, 61P, 61R
NRAS Melanomas
Hematopoietic malignancies
Codon 12: GGT(Gly, G) 12A, 12C, 12D, 12R, 12S, 12V
Codon 13: GGT (Gly, G) 13A, 13C, 13D, 13R, 13S, 13V
Codon 61: CAA (Gln, Q) 61E, 61H, 61K, 61L, 61P, 61R
Amino acid substitutions identified at codon 12, 13, and 61 of each RAS protein, highlighting in red the most frequently observed. Gly and G, glycine; Gln and Q, glutamine; A, alanine;
C, cysteine; D, aspartic acid; R, arginine; S, serine; V, valine; H, histidine; K, lysine; L, Leucine; P, proline; E, glutamic acid.
PHENOTYPICAL DIFFERENCES AMONG
RAS PROTEINS MUTATIONS
Early studies analyzing the biochemical consequences of
RAS mutations showed connections between HRAS specific
mutations and cell transformation (7, 8). These reports pointed
out that particular RAS mutations may modify the biochemical
behavior of RAS proteins including their ability to bind
GTP and GDP. Three decades later, additional differences
in RAS mutations biology with respect to endpoints such
as anchorage-independent growth or cell migration in many
types of cancers are being continuously reported (6, 22–25),
showing that RAS biological behavior is more complex than
previously thought.
Transforming Potential
Seeburg et al. were in 1984 the first to assess the transforming
potential of different HRAS mutations (7) by transfecting
rat fibroblasts with plasmids encoding 20 different HRAS
mutant variants at codon 12, which encodes for glycine.
The transforming potential of these mutants was assessed
by changes in colony morphology. Rat fibroblasts expressing
G12V, G12L, G12I, G12R, or G12T variants showed a fully
transformed colony morphology, with cells consistently round
and refractile that grew to the highest saturation densities.
Interestingly, the transfection with G12K- or G12Q-mutated
variants displayed low transformation, with foci induction after
2 or 3 weeks and cells with almost normal morphologies.
Similarly, fibroblasts transfected with G12S, G12M, G12C, G12Y,
G12F, G12W, G12H, G12D, G12E, G12A, and G12N plasmids
exhibited an intermediate transformation, with cells overgrowing
the monolayer but less striking changes in morphology than
the most potent mutations. However, similarly to glycine,
no transformation was observed with the G12P variant (7).
Later, HRAS mutations at codon 61 were analyzed by Der
et al. (8). NIH3T3 mouse fibroblast cells were transfected with
plasmids encoding 17 different amino acids at codon 61 and the
transforming potential was analyzed by foci formation (8). The
transfected cells displayed different transforming potential, from
very strong transforming mutants (Q61V, Q61L, Q61K, Q61A,
Q61C, and Q61R) to a very weak one, Q61G, which was ∼200-
fold lower than Q61V. Q61H, Q61I, Q61Y, Q61M, Q61T, Q61N,
Q61W, and Q61F mutants showed an intermediate spectrum
between weak and strong transformation. Moreover, Q61P and
HRAS WT failed to demonstrate any transformation (8). This
failure is not due to the impaired expression of the mutant
protein (7), but it could be explained by the fact that proline at
codons 12 or 61 of HRAS displays similar biological properties
as wild type (WT) HRAS (8). The overexpression of either WT
HRAS orHRASG12P orQ61P inNIH3T3 fibroblasts leads to cell
transformation (8). Moreover, based on HRAS structure, proline
at position 12 may cause a helix termination, resulting in a lower
transforming potential (26). These early observations suggest that
the transforming potential of RAS proteins also depends on the
substitution that replaces the original amino acid.
Later, Smith et al. similarly compared the transforming
potential of different KRAS mutations (22). NIH3T3 fibroblasts
were transfected with plasmids expressing WT, G12V, G12D,
G13D, and Q61H KRAS. All KRAS mutants exhibited foci
formation after 21 days, however codon 12 mutations had a
slightly greater transforming potential than mutations at codons
13 and 61 (G12V > G12D > G13D > Q61H) (Table 2) (22).
These intriguing data stimulated further studies in which the
role of the same mutation in different RAS proteins properties
has also been investigated. In that sense, Voice et al. compared
transforming potential of the G12V mutation among HRAS,
NRAS, KRAS4A, and KRAS4B proteins in different cell lines
(17). The focus forming abilities of HRAS and KRAS4A in
NIH3T3 and Rat-1 cells were ∼2- to 2.5-fold higher than those
of KRAS4B and NRAS. Interestingly, in RIE-1 cells, HRAS
and KRAS4A transforming potentials were 8.3- and 6.3-fold
higher than those of KRAS4B and NRAS (17), indicating that
Frontiers in Oncology | www.frontiersin.org 3 October 2019 | Volume 9 | Article 1088
Muñoz-Maldonado et al. Comparison of RAS Mutations in Cancer
T
A
B
L
E
2
|
P
h
e
n
o
ty
p
ic
a
ld
iff
e
re
n
c
e
s
a
m
o
n
g
R
A
S
p
ro
te
in
s
m
u
ta
tio
n
s.
C
h
a
ra
c
te
ri
s
ti
c
/m
u
ta
ti
o
n
K
R
A
S
4
A
G
1
2
V
K
R
A
S
4
B
G
1
2
V
H
R
A
S
G
1
2
V
N
R
A
S
G
1
2
V
K
R
A
S
G
1
2
A
K
R
A
S
G
1
2
C
K
R
A
S
G
1
3
D
K
R
A
S
Q
6
1
L
K
R
A
S
Q
6
1
H
K
R
A
S
G
1
2
D
K
R
A
S
G
1
3
C
K
R
A
S
G
1
2
V
K
R
A
S
G
1
2
R
N
R
A
S
Q
6
1
R
Tr
a
n
sf
o
rm
in
g
p
o
te
n
tia
l
H
ig
h
(1
7
)
L
o
w
(1
7
)
H
ig
h
(1
7
)
L
o
w
(1
7
)
H
ig
h
(2
2
)
M
id
(2
2
)
V
e
ry
h
ig
h
(2
2
)
V
e
ry
h
ig
h
(2
2
)
G
T
P
b
in
d
in
g
H
ig
h
(6
)
V
e
ry
h
ig
h
(6
)
H
ig
h
(6
)
Y
e
s
(2
2
)
H
ig
h
(6
)
In
st
rin
si
c
G
T
P
h
yd
ro
ly
si
s
V
e
ry
sl
o
w
(2
5
)
S
lo
w
(2
5
)
V
e
ry
sl
o
w
(2
5
)
V
e
ry
sl
o
w
(2
5
)
S
lo
w
(2
5
)
S
lo
w
(2
5
)
V
e
ry
sl
o
w
(2
5
)
V
e
ry
sl
o
w
(2
4
)
G
A
P
-m
e
d
ia
te
d
G
T
P
h
yd
ro
ly
si
s
S
lo
w
(2
5
)
V
e
ry
sl
o
w
(2
5
)
S
lo
w
(2
5
)
S
lo
w
(2
5
)
S
lo
w
(2
5
)
S
lo
w
(2
5
)
V
e
ry
sl
o
w
(2
4
)
A
n
c
h
o
ra
g
e
-
in
d
e
p
e
n
d
e
n
t
g
ro
w
th
Y
e
s
(1
7
)
N
o
/Y
e
s
(1
7
)
N
o
/Y
e
s
(1
7
)
Y
e
s
(1
7
)
Y
e
s
(2
3
)
Y
e
s
(6
)
Y
e
s/
N
o
(6
)
Y
e
s
(6
)
N
o
(2
3
)
Y
e
s/
N
o
(6
)
Y
e
s/
N
o
(6
)
Y
e
s
(6
)
M
ig
ra
tio
n
N
o
(1
7
)
Y
e
s
(1
7
)
F
a
st
(3
0
)
M
in
im
a
lly
(1
7
)
S
lo
w
(3
0
)
N
o
(1
7
)
Y
e
s
(6
)
Y
e
s
(6
)
Y
e
s
(6
)
S
u
m
m
a
ry
o
f
R
A
S
m
u
ta
n
t
p
ro
te
in
s
m
a
n
ife
s
ta
ti
o
n
s
a
c
c
o
rd
in
g
to
d
iff
e
re
n
t
s
tu
d
ie
d
c
h
a
ra
c
te
ri
s
ti
c
s
.
G
T
P,
g
u
a
n
o
s
in
e
-5
′ -
tr
ip
h
o
s
p
h
a
te
;
G
A
P,
G
T
P
a
s
e
-a
c
ti
va
ti
n
g
p
ro
te
in
s
.
the differences in mutant transforming potential are also cell
type-dependent (Table 2).
In addition to in vitro studies that have been performed
to elucidate the differences among RAS mutations functional
characteristics, xenograft models and genetically-engineered
mouse models have been used for that purpose as well (24,
27, 28). For example, Céspedes et al. identified the tumorigenic
potential of KRAS G12V and G12D mutations in vivo (27).
Both mutations generated tumors but cells harboring the G12V
mutation grew significantly faster than cells harboring the
KRAS G12D mutant variant (27). A later study by Haigis
et al. analyzed the transforming potential of KRAS and NRAS
G12D mutant proteins expressed in the colonic epithelium
of genetically-engineered mice (28). Animals harboring KRAS
G12D developed widespread hyperplasia throughout the colonic
epithelium, which also happened in adult mice. However, the
expression of NRAS G12D mutant variant in this tissue had
no effect, suggesting that KRAS might be the only RAS protein
modulating the homeostasis of the colon. Interestingly, KRAS
G12D mice did not develop colon cancer, indicating that the
expression of this mutant variant is not sufficient to promote
neoplasia (28). In addition, using a melanoma mouse model,
Burd et al. reported that homozygous NRAS G12D or NRAS
Q61R p16INK4a-deficient mice developed significantly more nevi
than control mice. However, mice harboring NRAS Q61R
triggered nevi formationmore frequently than animals harboring
NRAS G12Dmutation (p= 0.03) (24). Moreover, the penetrance
of the tumors was higher in NRAS Q61R mice than in NRAS
G12D animals, results that are in accordance with the frequency
of nevi formation. Nevertheless, tumor growth and histology
were similar between the NRAS G12D- and the NRAS Q61R-
induced tumors (24). Collectively these studies have formed a
basis for the notion that the different RAS mutations display
a wide variety of transforming potentials depending on various
factors including the codon site, RAS protein, and cell type.
GDP and GTP Binding
As mutations at codons 12, 13, and 61 cluster around the
nucleotide-binding site, amino acids exchange at these positions
may alter the interactions between RAS proteins and GTP or
GDP (25). In their 1986 manuscript, Der et al. also analyzed
the GDP and GTP binding affinity in WT and 17 different
HRAS mutants (8). Both GDP and GTP appeared to bind WT
HRAS or the HRAS Q61L mutant variant with the same affinity.
In addition, the kinetics of GTP hydrolysis between WT and
mutant HRAS was studied. All the analyzed mutants reduced
GTP hydrolysis compared to WT HRAS, which correlates with
the oncogenic activation of RAS. However, Q61L, Q61W, Q61N,
Q61G, Q61P, and Q61E mutants displayed indistinguishable
GTP hydrolysis, with one-eighth reduction in the rate compared
to WT HRAS (8). Interestingly, these HRAS mutants have
different transforming potentials, suggesting that compromised
GTP hydrolysis is necessary but not sufficient for a complete
RAS activation.
More than 30 years later, further studies continue reporting
differences in GTP binding and intrinsic or GAP-mediated
GTP hydrolysis (6, 22, 25). Smith et al. detected KRAS G12V
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in the GTP-bound conformation, which was consistent with
its high transforming potential (22). In addition, experiments
in MCF10A cells transduced with different KRAS mutations
revealed that WT KRAS and KRAS G12D and G13D were able
to bind GTP with a similar affinity as control cells, which only
express endogenous KRAS, after EGF stimulation (6). In contrast,
KRAS G12C, G12V, and G13C mutants showed an increase
in GTP-binding up to 2-fold and up to 5- to 6-fold in KRAS
Q61H mutant compared to control cells (Figure 1A, Table 2)
(6). A similar study analysing WT KRAS and KRAS mutations
G12A, G12C, G12D, G12R, G12V, G13D, Q61L, and Q61H
showed that the kinetics of GDP-GTP exchange were similar
between all mutant proteins and WT KRAS, with the exception
of KRAS G13D (25). This mutation showed a faster GDP and
GTP exchange than the WT KRAS, suggesting that KRAS G13D
mutant protein might be auto-activated by nucleotide exchange
easier than other mutant variants. Moreover, the fast nucleotide
exchange of the KRAS G13D mutant may contribute to a more
aggressive biology of tumors harboring this mutation (25).
Additionally, this study also reported that while KRAS
G12A, G12R, Q61H, and Q61L decreased GTP hydrolysis speed
approximately by 40- to 80-fold as compared to WT KRAS, the
G12C mutation had a minimal impact in this respect. Regarding
this endpoint, KRAS G12D, G12V, and G13D mutant proteins
displayed an intermediate effect (25). When analyzing GAP-
mediated GTP hydrolysis, all KRAS mutants showed 97–99%
reduction in GAP-mediated GTP hydrolysis compared to WT
KRAS. In the case of KRAS G12A and Q61L, the GAP-stimulated
rate was 15- to 25-fold higher than the intrinsic GTP hydrolysis
rate, which may suggest that these mutants keep part of the
GAP-mediatedGTP hydrolysis activity (Figure 1A,Table 2) (25).
The GAP-mediated and the intrinsic nucleotide exchange
were studied in tumors derived from an in vivomelanoma model
(24). WT NRAS and NRAS G12D and Q61R mutant proteins
showed similar GDP exchange rates, but differed significantly in
their GTP exchange rates, with WT NRAS showing the fastest
GTP exchange and NRAS Q61R the slowest. These differences
were more significant when the reaction was catalyzed by GEFs.
Moreover, NRAS Q61R mutant protein also showed the slowest
intrinsic GTP hydrolysis (1,150- and 2,300- times slower than
NRAS G12D and WT NRAS, respectively) (Table 2) (24).
These data suggest that not only intrinsic GTP hydrolysis
is important for mutant RAS transformation. GAP-mediated
nucleotide exchange might also have an effect on RAS mutant
proteins transformation, which makes it more difficult to
anticipate the transforming potential of a particular RAS
mutant variant.
Anchorage-Independent Growth
Anchorage-independent growth is the ability of transformed
cells to grow in suspension or unattached to any matrix (6), an
associated characteristic for tumor metastasis regulated by the
RAS/RAF/MAPK signaling pathway (29). Seeburg et al. reported
that with the exception of HRAS WT and HRAS G12P, all the
HRAS codon 12 mutants were able to grow in soft agar (7),
results paralleling their data on transforming potential of these
mutant proteins.
Voice et al. also assessed the anchorage-independent growth
of the G12V mutation of different RAS proteins in RIE-1 and
Rat-1 cells (17). Unlike the KRAS4B G12V-harboring RIE-1 cells,
same cells expressing the KRAS4A G12V mutants were able to
grow in soft agar, correlating with the ability of these proteins
to form foci. However, the HRAS G12V cells failed to grow
in soft agar despite their ability to form foci in RIE-1 cells,
whereas the NRAS G12V mutation enabled RIE-1 cells to grow
in soft agar despite its little transforming activity. Interestingly,
all these RAS G12V proteins enabled growth in soft agar when
expressed in Rat-1 fibroblasts, although KRAS4B and NRAS
showed reduced transforming potential in this cell line (Table 2)
(17). This suggests that the ability to grow independently of
anchorage depends on a particular cellular intrinsic milieu rather
than on the RAS proteins harboring the substitution.
Later, immortalized human bronchial epithelial cells with
specific shRNA knockdown of p53 mRNA expressing KRAS
G12C were able to form colonies in soft agar compared to
KRAS G12D- and KRAS WT-transfected cells (23), suggesting
that the genetic background could also affect the phenotypical
manifestation of mutant RAS variants. Moreover, Stolze et al.
showed that the overexpression of KRASG12D, G13C, andG13D
in MCF10A cells yielded a very high colony number in soft
agar. However, the expression of these mutants at physiological
levels did not confer anchorage-independent growth (6). In
the case of clones expressing KRAS Q61H, G12V, and G12C,
a slight increase in colony number was observed compared
to control cells expressing endogenous KRAS, which also
correlated with the highest GTP-bound levels reported in the
same study (Table 2) (6). Collectively, these results suggest that
some RAS mutant proteins might have the ability to grow
independent of anchorage, which may depend on cell type and
genetic background.
Migration
Cell migration is controlled by several RAS downstream
pathways, such as the RAS/RAF/MAPK pathway (29). As this
process involves cancer cells local invasion and metastasis (6),
several studies analyzed the migration abilities of distinct RAS
mutant proteins (6, 17, 30). Voice et al. reported that the KRAS4B
G12V variant could accelerate COS-7 cells migrationwhile HRAS
G12V had a minimal effect, compared with cells transfected
with GFP alone. However, KRAS4A G12V- and NRAS G12V-
expressing cells were unable to migrate, even at higher expression
levels (17). A later study byWalsh et al. (30) showed that KRAS4B
G12V-transfected REF-52 cells migrated at the speed of 18µm/h,
while the HRAS G12V cells at 12 µm/h (30). In addition, Stolze
et al. reported that the overexpression of KRAS G12D, G12V,
and G13D enabled MCF10A cells migration (6). Similarly to
KRAS-overexpressing mutant proteins, control cells were able
to migrate after EGF addition (Table 2). However, none of the
studied mutations expressed at physiological levels increased
migration abilities compared to WT KRAS or control cells,
which expressed endogenous KRAS (6). Therefore, these results
contrast with previous studies (17, 30) as only the overexpression
of KRAS mutant variants leads to cell migration.
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FIGURE 1 | RAS downstream signaling pathways. RAS canonical and non-canonical downstream signaling pathways are represented in green and blue, respectively.
RAS proteins non-canonical mutations are highlighted in italics. (A) RAS proteins signal between “on” and “off” conformations, given by the binding of GTP and GDP,
(Continued)
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FIGURE 1 | respectively. The transition from the inactive to the active form is catalyzed by guanine nucleotide exchange factors (GEFs), while the GTPase-activating
proteins (GAPs) control the inverse reaction. RAS-GTP proteins interact with different downstream effector proteins to activate several signaling pathways. RAS
mutant variants which decrease GAP-mediated GTP hydrolysis and strongly bind GTP are represented. (B) RAS canonical downstream pathways: RAS/RAF1/MAPK
and PI3K/AKT signaling pathways, and their cellular output. The ability and relative strength of different RAS mutant proteins to interact or activate effector proteins are
mentioned. (C) A representation of the non-canonical downstream pathways of RAS and their cellular output. GEFs, guanine nucleotide exchange factors; GAPs,
GTPase-activating proteins; RAF1, rapidly accelerated fibrosarcoma 1; ERK, extracellular signal-regulated kinase; MEK, mitogen-activated protein kinase; PI3K,
phosphatidylinositol 3-kinase; AKT, protein kinase B; PDK, 3-phosphoinositide-dependent protein kinase; ELK, ETS Like-1 protein; PIP3, Phosphatidylinositol
(3,4,5)-triphosphate; PKN, protein kinase N1; SGK, serum and glucocorticoid-regulated kinase; RAC, Ras-related C3 botulinum toxin substrate 1; RAL, Ras-related
protein Ral; TIAM1, T-lymphoma invasion and metastasis-inducing protein 1; PAK, p21-activated kinase; RHO, Ras homologous protein; RALGDS, Ral guanine
nucleotide dissociation stimulator; PLD, phospholipase D; JNK, c-Jun N-terminal kinase; RLIP76, ralA-binding protein 1; ARF6, ADP-ribosylation factor 6; RASSF1,
Ras associated domain-containing protein 5; MST1, serine/threonine kinase 4; ↑, high interaction or downstream proteins activation; ↑↑, very high interaction or
downstream proteins activation; ↓, low interaction or downstream proteins activation; ↓↓, very low interaction or downstream proteins activation; +, interaction or
activation of the downstream effector proteins; –, inability to interact or activate the downstream effector protein.
Animal model studies also evaluated metastatic capacities
of tumors harboring KRAS mutations (31, 32). A recent in
vivo study by Tang et al. analyzed tumor formation and their
metastatic capacity in KRAS G12D p53−/− mice (31). As
compared to KRASWT/WT p53−/− and KRASWT/WT p53+/+
(wild type) mice, animals harboring both KRAS G12D and
p53−/− alterations developed tumors with 100% penetrance and
their size increased over time. Moreover, tumors from KRAS
G12D p53−/− mice were able to metastasize to the liver, spleen
and kidney whereas tumors formed in KRASWT/WT p53−/− and
WT animals were not (31). Previously, Whipple et al. studied
the involvement of the heparin sulfate proteoglycan Glypican-
1 (GPC1) in KRAS G12D-driven mouse model of pancreatic
cancer (32). At 65 days of age, 14 of 14 animals harboring
wild type GPC1 developed large pancreatic tumors that invaded
the surrounding organs, whereas 16 of the 20 GPC1−/− mice
developed smaller and non-invasive tumors (32). Moreover, four
primary cancer cell lines were derived from tumors developed in
GPC1+/+ (F1015 and F1048) and GPC1−/− (J444 and J1032)
mice. These cell lines formed tumors in GPC1+/+ nude mice.
However, in vitro studies revealed that J444 and J1032 cells
exhibited decreased invasion capacities in response to FGF-
2 compared to F1015 and F1048 primary cancer cells (32).
To determine whether the loss of GPC1 was also involved
in a reduction of invasion in vivo, tumor fragments from
GPC1+/+ and GPC1−/− mice were implanted into the pancreas
of athymic GPC1+/+ and GPC1−/− animals. Two weeks after
the implantation, only 2 out of 14 GPC1−/− mice developed
metastasis in the mesentery, while 9 out of 15 GPC1+/+ mice
developed several (over 100 per animal) mesenteric metastases
and three of them also showed multiple renal metastases (32).
Therefore, these two studies suggest that not only KRAS G12D-
expressing tumors are able to migrate andmetastasize in vivo, but
also other RAS mutant proteins may have the capacity to invade
the surrounding tissues, as reported by in vitro studies (6, 17, 30).
All together these findings strongly indicate that point
mutations at codons 12, 13, and 61 of RAS display different
phenotypical characteristics compared to WT RAS. Depending
on the RAS isoform and the amino acid substitution, RAS
mutant proteins differ in their transforming ability, GTP binding,
anchorage-independent growth and migration capacities. But
these results also suggest that RAS mutations show a different
biological behavior depending on the cell type where they
are expressed, adding complexity to our understanding of
RAS biology.
MUTANT RAS PROTEINS DIFFER IN THEIR
BIOCHEMICAL SIGNALING
Wild type RAS proteins are able to activate different signaling
pathways depending on particular cell type, tissue and their
subcellular localization (21). As codon 12, 13, and 61 mutations
are located around the nucleotide-binding site, it has been
suggested that the nucleotide exchange may alter the affinity of
mutant RAS proteins for downstream effectors proteins (17, 25).
Activation of the RAF1/MAPK Pathway
The RAF1 serine/threonine kinase is one of the best characterized
RAS effector proteins, located directly downstream of RAS in
the MAPK pathway (25). Considering that point mutations at
codons 12 and 61 of HRAS differ in their phenotypical properties
as previously reported (7, 8), Voice et al. hypothesized that
mutant RAS proteins might activate RAF1 differentially (17).
The co-transfection of WT RAF1 and G12V HRAS, NRAS,
KRAS4A, and KRAS4B in COS-1 cells confirmed that RAS
proteins differ in their ability to activate RAF1. KRAS4B activated
RAF1 8.4-, 4.4-, and 2.3-fold better than HRAS, NRAS, and
KRAS4A, respectively, proposing the following hierarchy in
RAF1 activation by these RAS proteins: KRAS4B > KRAS4A
>>> NRAS > HRAS (Figure 1B) (17). Later, Hunter et al.
analyzed the affinity of different KRAS mutants for the RAS-
binding domain (RBD) of RAF1 (25). KRAS G12A, G12C, G13D,
Q61L, and Q61H showed 1.2- to 2.3-fold decrease in relative
affinity compared to WT KRAS and KRAS G12D, G12R and
G12V displayed even more pronounced decrease in affinity for
RAF1 (4.8-, 6.2-, and 7.3-fold, respectively) (Figure 1B, Table 3)
(25). These results contrast with those reported by Voice et al.
(17) where KRAS G12V showed a high activation of RAF1.
However, these differences could be related to the method used
in each study to detect RAF1 activation.
Other works analyzed the activation of the MAPK pathway
by assessing ERK activation through its phosphorylation status
(6, 33). For example, transduction of primary rat hepatocytes
with HRAS G12V, but not with KRAS G12V, showed a
strong activation of ERK2 independently of EGF stimulation
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TABLE 3 | Interaction and activation of different RAS proteins downstream effectors.
Characteristic/mutation KRAS4A
G12V
KRAS4B
G12V
HRAS
G12V
NRAS
G12V
KRAS
G12A
KRAS
G12C
KRAS
G13D
KRAS
Q61L
KRAS
Q61H
KRAS
G12D
KRAS
G12R
KRAS
G12V
NRAS
G12D
NRAS
Q61R
RAF1
interaction
High (17) Very high
(17)
Very low
(17)
Low (17) High (25) High (25) High (25) High (25) High (25) Low (25)
– (27)
Very low
(25)
Very low
(25)
+ (27)
High (24) Low (24)
ERK
activation
Strong
(33)
–(27)
+ (28)
Low (33)
+ (27)
– (28)
+ (24)
+ (24)
MEK
activation
+ (28) – (28)
PI3K
interaction
+ (27) + (27) Low (24)
AKT
activation
Low (23) Strong
(27)
Decreased (28)
Low (23)
(27)
Decreased
(28)
+ (24)
+ (24)
70S6K
activation
Strong
(23)
Strong
(23)
RPS6
activation
High (6)
RAC
interaction
Strong
(30)
Low (30) – (28) – (28)
RAL
interaction
+ (23) – (23, 28) – (28)
Summary of the activation of downstream signaling pathways by RAS mutant proteins. Proteins activation was assessed by phosphorylation at different residues. +, interaction or activation of the effector; –, inability to interact or
activate the downstream effector protein; RAF1, rapidly accelerated fibrosarcoma 1; ERK, extracellular signal-regulated kinase; MEK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; 70S6K,
ribosomal protein S6 kinase 1; RPS6, ribosomal protein S6; RAC, Ras-related C3 botulinum toxin substrate 1; RAL, Ras-related protein Ral.
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(33), revealing that different RAS proteins harboring the same
mutation activate downstream signaling pathways differently. On
the other hand, a more recent study by Stolze et al. reported
no differences in ERK phosphorylation levels in MFC10A cells
expressing KRAS G12D, G12V, G12C, G13D, G13C, and Q61H
at low levels compared to WT KRAS or control cells, expressing
endogenous KRAS (Figure 1B, Table 3) (6). These data suggest
that not only the cell type but also the level of expression may
influence the pattern and intensity of RAS mutations signaling
pathways activation.
Mutant RAS signaling differences have also been identified
in tumors derived from animals. Céspedes et al. reported that
mouse tumors expressing KRAS G12V, but not G12D, were able
to interact with RAF1 and showed a high phosphorylation of
ERK (27). Interestingly, Haigis et al. reported different results
concerning KRAS G12D (28), where KRAS G12D but not NRAS
G12D could activate MEK and ERK in colonic epithelium of
genetically engineered mice (Figure 1B). However, the activation
of both KRAS G12D and NRAS G12D proteins at the same
time only appeared in the differentiated cells at the top of the
colonic crypt and not in the undifferentiated cells at the bottom
of the crypt, suggesting that the exact activation pattern of ERK
depends on the cell type (28). Recently, a study by Burd et al.
revealed that NRAS Q61R bound RAF1 with lower affinity than
WT NRAS or NRAS G12D in melanoma. However, both NRAS
Q61R and G12Dmutant proteins activated ERK at variable levels
(Figure 1B,Table 3) (24), suggesting that the activation ofMAPK
pathway in melanoma is codon-independent.
PI3K/AKT/mTOR Pathway Activation
RAS proteins also trigger the activation of the PI3K/AKT/mTOR
pathway to promote cell survival by activating survival factors
and inhibiting apoptotic proteins (5). Therefore, different in
vitro (6, 23) and in vivo (24, 27, 28) studies also assessed the
activation of this pathway by the interaction of various RAS
mutated variants with PI3K and different downstream proteins
phosphorylation, such as AKT, 4EBP, or RPS6. The comparison
of KRAS G12C and G12V with WT KRAS in a panel of 67 non-
small cell lung cancer cell lines showed that these mutations
decreased AKT activation compared to WT KRAS (Figure 1B)
(23). Despite this low activation of AKT, cells expressing KRAS
G12C or G12V showed the same phosphorylation levels of
70S6K and 4EBP proteins compared to WT KRAS in the
absence of serum whereas the addition of serum to the media
enabled KRAS G12C and G12V to strongly phosphorylate 70S6K
compared to WT KRAS (Figure 1B, Table 3) (23). Later on,
Stolze et al. reported that KRAS G12D, G12V, G12C, G13D,
G13C, and Q61H expressed at low levels in MCF10A cells did
not show higher phosphorylation of PDK1 and AKT compared
to WT KRAS or control cells which only express endogenous
KRAS (6). Nevertheless, both KRAS G13D low expression
as well as overexpression were associated with a high RPS6
phosphorylation upon EGF (Table 3), indicating that this mutant
enabled mTOR pathway activation but seemingly not through
the PI3K/AKT pathway (6). Interestingly, the results reported for
KRAS G12D in this study are inconsistent with those obtained
by Ihle et al. (23), suggesting that the cell type and/or the
genetic background may alter the activation of the downstream
signaling pathways.
In mouse xenograft tumors, Céspedes et al. showed that both
KRAS G12V and G12D mutants were able to interact directly
with PI3K (27). However, KRAS G12V was unable to activate
AKT despite its interaction with PI3K whereas KRAS G12D
strongly activated AKT (27). Contrary, KRAS G12D as well as
NRAS G12D expressed in the mouse colonic epithelium showed
a decrease in AKT phosphorylation compared to WT animals
(Table 3) (28), proposing once again that cell type may alter the
downstream signaling pathways activation. In addition, studies
employing a mouse model of melanoma revealed that NRAS
Q61R binds PI3K with lower affinity than WT NRAS or NRAS
G12D while NRAS G12D and Q61R activate AKT at variable
levels (Figure 1B, Table 3) (24), indicating that the activation of
the PI3K pathway in melanoma is codon-independent.
Other Effectors Activation
RAS proteins can also interact and activate effectors that do
not belong to the MAPK and the PI3K canonical cascades.
For example, RAC, a subfamily of small GTPases of the
RHO family, can interact with RAS via the RacGEF called
Tiam1. The RAS/RAC signaling pathway controls several cellular
functions through the regulation of actin cytoskeleton, including
cell morphology, locomotion, and polarity (34). Another RAS
downstream effector subfamily is the RAL group of proteins,
which are involved in membrane trafficking, proliferation,
survival and metastasis in many types of cancer (35).
Walsh and Bar-Sagi studied the differential activation of
RAC in COS-1 cells transduced with KRAS4B G12V and HRAS
G12V (30). Cells expressing KRAS4B G12V activated RAC more
effectively than HRAS G12V-transduced cells (30). Moreover,
in vivo studies also analyzed the modulation of RAC (28). The
expression of either KRAS or NRAS G12D in the mouse colonic
epithelium did not promote RAC modulation. In addition,
this study revealed that KRAS and NRAS G12D were unable
to modulate RAL activation (Table 3), indicating the limited
signal activation of these mutants in vivo (28). These results are
consistent with a later in vitro study (23), in whichWTKRAS and
KRAS G12C, but not KRAS G12D, where able to activate RALA
and RALB effector proteins (Table 3) (23).
Furthermore, Stolze et al. analyzed whether any of the KRAS
codon 12, 13, and 61 mutations included in the study was able to
increase the activation of EGFR and p53 (6). Only KRAS G13D
ectopically expressed in MCF10A breast cancer cells promoted
an increase in total and phosphorylated EGFR. Moreover, KRAS
G13D stimulated a strong phosphorylation of p53 at serine 15,
a site known to be phosphorylated by the master DNA damage
response kinase ATM, which suggests that particularly the KRAS
G13D mutant might induce a DNA damage response under
replicative stress (6). As other KRAS mutants did not show the
activation of EGFR and p53, these authors suggest that this
activation could be the biological explanation of the favorable
clinical outcome of colorectal cancer patients harboring KRAS
G13D mutation treated with anti-EGFR therapy compared to
patients with KRAS codon 12 mutations (6).
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Signaling Pathway Activation and Outcome
Several studies assessing the impact of RAS mutations on cell
behavior correlated the signaling pathways activated by a specific
mutation with a particular outcome such as cell death or
cell cycle redistribution (27, 28, 30, 33). Joneson and Bar-Sagi
reported that overexpression of HRAS G12V induced apoptosis
in a panel of primary and immortalized cells (36). However,
the co-transfection of REF-52 fibroblasts with HRAS G12V
and activated RAC blocked HRAS G12V-induced apoptosis,
indicating that RAC signaling pathway is sufficient to antagonize
RAS proapoptotic signals (36). As KRAS4B G12V and HRAS
G12V differentially activate the RAC signaling pathway (30),
Walsh and Bar-Sagi hypothesized that these mutant variants may
differ in their ability to induce apoptosis (30). The overexpression
of HRAS G12V in REF-52 fibroblasts induced apoptosis in 38%
of the cells whereas the overexpression of KRAS4B G12V had no
effect on cell viability, results that are consistent with the RAC
activation levels reported in this work for each mutant (30).
Céspedes et al. described that expression of KRAS G12V
in xenograft tumors enhanced Retinoblastoma (Rb) protein
phosphorylation and was accompanied by an increase in cyclin
B1 expression. This could be related to the high proliferation
rate of these tumors and their fast G1/S and G2/M transitions
(27). However, no differences in the level of procaspase 3 or
9 proteolysis were detected between KRAS G12V and G12D
tumors, leading to a similar activation of apoptosis (27). In
a later study, Haigis et al. exposed genetically engineered
mice to 2.5% dextran sodium sulfate (DSS). Mice expressing
WT KRAS or KRAS G12D in the colonic epithelium were
sensitive to DSS-induced apoptosis in this tissue, whereas in mice
expressing NRASG12D little or no apoptotic effect was observed.
However, NRAS G12D mice were sensitive to irradiation-
induced apoptosis in the colonic epithelium, indicating that the
effect of this mutationmight depend on the apoptotic stimuli and
the activated cell death pathway (28).
Along similar lines of investigations, Rosseland et al. studied
proliferation of primary rat hepatocytes transfected with HRAS
G12V or KRAS G12V (33). Compared to control cells expressing
the yellow fluorescent protein, the proliferation rate of HRAS
G12V, but not of KRAS G12V, was increased after EGF
stimulation (33). In addition, an earlier study by Oberhammer
et al. reported that TGF-βI increased the incidence of apoptosis
in hepatocytes by 5-fold, suggesting that TGF-βI is involved
in the initiation of apoptosis in the liver (37). Based on these
results, Rosseland et al. tested whether HRAS G12V and KRAS
G12V were able to induce apoptosis in rat hepatocytes after
TGF-βI stimulation (33). Hepatocytes expressing HRAS G12V or
KRAS G12V had reduced apoptosis compared to untransfected
control cells, demonstrating that both RAS mutant proteins have
a pro-survival effect (33). To further investigate the signaling
pathways involved in this phenomenon, PI3K and ERK pathways
were blocked with different inhibitors. In untransfected control
cells, apoptosis was only slightly increased after ERK pathway
inhibition while PI3K inhibition strongly increased apoptosis,
indicating that both ERK and PI3K pathways are involved in
survival of primary hepatocytes (33). In HRAS G12V-transfected
hepatocytes, the inhibition of ERK or PI3K pathways did not
reduce apoptosis after TGF-βI stimulation. However, in KRAS
G12V-transfected cells, only the inhibition of PI3K pathway
showed an increase in hepatocytes apoptosis (33). This suggests
that apoptosis is triggered through different pathways depending
on the RAS isoform and mutation.
Taken together, a single amino acid change at codons 12, 13,
or 61 of RAS alters the interaction of these proteins with the
downstream effectors. Depending on the RAS protein and the
amino acid substitution, RAS mutants activate differently the
canonical and non-canonical downstream signaling pathways in
vitro and in vivo. Moreover, the amino acid substitutions have
been correlated with a particular outcome, such as proliferation
or cell death and hence these observations should be further
exploited and considered for the choice of treatment of patients.
RAS MUTATED VARIANTS DIFFER IN
THEIR TRANSCRIPTOMIC, PROTEOMIC
AND METABOLOMIC PROFILES
Protein and metabolic stress are two recognized hallmarks
of cancer in which different cellular signaling pathways are
altered to confer an advantage to cancer cells and sustain
their growth and proliferation (38). To get insights into
global cellular networks that underlie various RAS mutated
variants, various works have been assessing the transcriptomic,
proteomic/phosphoproteomic and metabolic profile of RAS
mutant variants to possibly associate and understand the basis
of their phenotypic disparities (6, 39–41).
Transcriptomics
Roberts et al. analyzed whether the expression pattern of
2,100 genes involved in cancer progression differ between
KRAS G12V- and HRAS G12V-expressing Caco-2 colorectal
adenocarcinoma cells and found 71 differentially regulated genes
(42). KRAS G12V significantly up-regulated the expression of
genes in the cytokine/chemokine family, for example CD40L,
CD27L, CD30L, and TRAF-5 and regulated processes related
to immune response, development, nucleotide excision repair,
cell proliferation, transcription and cytokine signaling (42).
HRAS G12V-expressing cells up-regulated vimentin and down-
regulated villin and fibronectin, correlating with the main
biological processes controlled by HRAS G12V such as cell-
matrix and cell-cell adhesion, protein biosynthesis, integrin-
mediated signaling, cell motility and cell cycle checkpoint
control, most of them involved in the epithelial-mesenchymal
transition (42). In addition, this work assessed changes in the
transcriptome profile in vivo, revealing 26 genes differentially
expressed between KRAS G12V and HRAS G12V tumors. Up-
regulation of Notch signaling, cell motility or microtubule
cytoskeleton were detected in KRAS G12V whereas genes
involved in cell adhesion and motility were deregulated and
those involved in organogenesis/angiogenesis and cytokinesis
processes down-regulated in HRAS G12V tumors (42). Later, to
provide insights into the differential response of KRAS G12D
and KRAS G13D mutant variants to anti-EGFR therapy, Stolze
et al. compared the gene expression of these mutants and
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WT KRAS (6). The analysis of 2,487 genes demonstrated that
WT KRAS and control MCF10A cells, expressing endogenous
KRAS only, had a similar expression profile, while KRAS G12D-
and G13D-expressing cells showed a different one, clustering
them separately from each other and from the WT KRAS and
control cells (6). Moreover, this work identified, 11,207 and
1,011 genes significantly up- and down-regulated, respectively,
in KRAS G13D compared to KRAS G12D-expressing cells
(6). The analysis of the top 300 up- and down-regulated
genes in both mutants and their comparison to luminal
and basal/mesenchymal breast cancer gene expression profiles
reported previously (43, 44), associated KRAS G13D with the
basal/mesenchymal and KRAS G12D with the luminal breast
cancer subtype. Thus, KRAS G13D mutant variant highly
expressed genes such as those encoding for integrins, collagens,
and proteases, compared to KRASG12D (6). Furthermore, Stolze
et al. were able to identify mutation-specific signaling networks:
87 out of 300 top up-regulated genes were included in a cluster
associated with cytokine-induced cell migration. In this cluster,
the top up-regulated cytokines were CXL1, IL1B, and IL8, which
showed >10-fold increase in their transcription in KRAS G13D-
expressing MCF10A cells compared to KRAS G12D-expressing
cells (6).
Recently, KRAS G13D transcriptomic profile has been
reported also by Charitou et al. for the isogenic HKe3 colorectal
cancer cell line expressing WT KRAS or KRAS G13D (40). More
than 6,000 genes were identified to be differentially expressed
between WT KRAS- and KRAS G13D-expressing cells. Pathway
analysis of up-regulated genes revealed that ribosome biogenesis,
mRNA translation, regulation of gene expression andmetabolism
were among the most significantly enriched processes in cells
expressing KRAS G13D (40). Metabolic stress is a recognized
hallmark of cancer. To respond to the high energetic demand,
cancer cells increase ribosome biogenesis to translate mRNAs
into proteins in response to their high metabolic rate. In this
respect, some metabolic pathways were also up-regulated in
KRAS G13D-expressing cells compared toWT KRAS-expressing
cells. These pathways include glycolysis/gluconeogenesis, steroid
biosynthesis and glycine, serine and threonine metabolism (40).
The steroid biosynthesis pathway has cholesterol as its final
product. It has been reported that oncogene-transformed cells
require high levels of cholesterol to support their rapid growth
(45, 46). These results suggest that KRAS G13D-expressing
cells might have a higher metabolic rate compared to cells
expressing other KRAS mutant variants. Moreover, among the
down-regulated genes in the KRAS G13D-expressing HKe3
cells, the most enriched pathways were the type I interferon
signaling pathway and the antigen processing and presentation
pathway, which may help cancer cells to evade the host immune
response (40).
Jiang et al. analyzed the differences in both protein and
microRNA (miRNA) gene expression of NRAS Q61K-, Q61L-,
and Q61R-driven melanomas compared to those expressing WT
NRAS (47). One thousand one hundred fifty protein-coding
genes were significantly differentially expressed, with 469 and 681
up- and down-regulated, respectively, in NRASQ61K, Q61L, and
Q61R samples compared to the WT NRAS samples. In the case
of miRNAs, the expression of 49 miRNAs was altered, with 26
and 23 up- and down-regulated, respectively (47). Moreover, this
work identified pathways associated with these deregulated genes
and miRNAs; the most significant ones in both deregulated genes
and miRNAs were the MAPK signaling pathway, followed by
the PI3K/AKT and the CDK/4/6/Rb pathways (47). The MAPK
pathway is altered in most melanomas, while PI3K/AKT pathway
is involved in melanoma initiation and its therapeutic resistance
(48). In addition, CDK4 is a regulator of the G1/S cell cycle
checkpoint, and its targeting using Palbociclib has demonstrated
antitumor activity in melanoma (47). Other signaling pathways
were also enriched in NRAS-mutated melanoma, including
pathways involved in calcium, TGF-β, and WNT signaling, actin
cytoskeleton, focal adhesion and axon guidance, suggesting them
as novel candidate pathways for melanoma treatment (47).
Proteomics and Phosphoproteomics
Hammond et al. investigated proteomics and
phosphoproteomics signatures of isogenic SW48 colorectal
cancer cell lines expressing either WT KRAS or KRAS G12D,
G12V, or G13D variants (49). Hierarchical clustering of
proteomic and phosphoproteomic data revealed that KRAS
G12D- and G12V-expressing cells had similar signatures,
but these were different from KRAS G13D-expressing cells.
KRAS G13D showed more proteins and phosphopeptides
up-regulated (around 50% compared to WT KRAS) than KRAS
G12D-expressing cells (<10% compared to WT KRAS) (49).
These findings suggest that specific mutated codons define
different proteomic and phosphoproteomic signatures. In
addition, same authors assessed in this work proteins and
phosphoproteins differentially expressed in KRAS G12D and
G13D to determine whether a codon-specific signature could
be found (49). The analysis of the proteomes revealed that
the expression of mitochondrial proteins involved in oxidative
phosphorylation was decreased in KRAS G13D-expressing
SW48 cells compared to KRAS G12D-expressing cells. Moreover,
KRAS G13D showed a decrease in 5 members of the cytochrome
bc1 complex (complex III) and succinate dehydrogenase of
complex II of the mitochondrial respiratory chain. In contrast,
the expression of aldehyde dehydrogenase (ALDH3A1) was
increased in KRAS G13D-expressing cells and decreased
in KRAS G12D-expressing SW48 cells (49). Regarding the
phosphoproteomic data, MET Thr995 and Caveolin-1 Ser37
sites exhibited >10-fold increased abundance in KRAS G12D
as compared to KRAS G13D, explained by an increase in
protein expression, while BRAF Ser729 phosphorylation was
decreased in KRAS G12D vs, G13D-expressing cells. These
results were further confirmed in a panel of 275 lung, pancreas
and colon cancer cell lines harboring KRAS codon 12 and 13
mutations or WT KRAS (49). In addition, this work identified
the doublecortin-like kinase 1 (DCLK1) protein levels to be
at least 8-fold up-regulated in KRAS G12D-expressing SW48
cells compared to WT KRAS-expressing cells. However, qPCR
analysis revealed that the increased levels of DCLK1 are due to
transcriptional up-regulation, and this increase in the mRNA
level is reversed upon KRAS knockdown, indicating that KRAS
directly regulates DCLK1 expression (49). DCLK1 is frequently
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overexpressed in colorectal cancer (50) and has been identified
as a colorectal cancer stem cell specific marker, whose depletion
promotes polyps regression (51). Moreover, a KRAS synthetic
lethal screening previously identified the related kinase DCLK2
as a hit in the colorectal DLD-1 cell line (52), suggesting DCLK1
as a potential target for combination therapy in the context of
KRAS-mutated colorectal cancer.
Concerning HRAS mutant variants, Doll et al. profiled the
proteomic and phosphoproteomic changes in HRAS G12V-
transformed normal human astrocytes (53). Two hundred
and seventy-eight phosphosites in 154 proteins and 245
phosphorylation sites in 160 proteins were up- and down-
regulated, respectively, in WT HRAS- vs. HRAS G12V-
expressing cells. The analysis of these up-regulated phosphosites
revealed that the MAPK, PI3K/AKT and mTOR pathways were
significantly up-regulated in HRAS G12V-expressing astrocytes
as compared to WT HRAS cells (53). In the MAPK pathway,
Sprouty 4, whose expression is induced by this pathway, showed
10-fold upregulation at protein level. Regarding PI3K/AKT, the
Niban protein (FAM129A), which regulates the phosphorylation
of the transcription factor EIF2A, showed 2-fold upregulation
in HRAS G12V-expressing cells. Moreover, the phosphorylation
of RPTOR on Ser863 showed a 2.6-fold upregulation (53).
This phosphosite is involved in mTORC1 activation, whose
signaling activates different transcription factors involved in
transcription of cell proliferation and survival proteins (54).
This work also identified other deregulated proteins downstream
of HRAS. For example, six of the 13 RAL direct downstream
effectors of RAS involved in endocytosis and gene expression
(Figure 1), including RALA and RALB, showed 2-fold or
higher upregulation at protein level (53). Collectively, these
results indicate that HRAS G12V mainly activates the canonical
downstream pathways of RAS, triggering changes in gene
expression that facilitate cancer cells proliferation and survival.
Interestingly, Santra et al. recently reported differences in
HRAS G12V signaling according to its subcellular localization
in HeLa cells (41). Three hundred and ninety-seven proteins
that interact with HRAS G12V were identified across plasma
membrane (PM), lipid rafts (LR), endoplasmic reticulum (ER)
andGolgi apparatus (GA), out of which 341 were new interactors.
Only 5% of the interactors were identified in all subcellular
localizations, whereas ∼53% were specific for one of the
localizations (41). The pathway enrichment analysis revealed
that HRAS G12V not only regulates receptor tyrosine kinase
(RTK) signaling, but also biosynthesis and metabolic pathways
mainly from the ER, while immune signaling is triggered from
the GA. Additionally, lipid biosynthesis pathways were also
enriched (41), a finding which might be related to changes in
cellular metabolism. This work also assessed changes in the
phosphoproteome of HRAS G12V-expressing cells according to
its subcellular localization (41). One thousand four hundred
sixty-one phosphosites in 1,078 proteins were differentially
phosphorylated, with 74% of the phosphosites activated at LR
and PM (41). The analysis of the enriched pathways showed that
HRAS G12V-expressing cells regulate RTK signaling and other
signaling pathways, such as WNT, MAPK, or insulin signaling
pathways (41). The results of this work confirm previously
described findings that apart of subcellular localization-specific
differences in RAS WT proteins signaling (20, 21), also RAS
mutant variants may signal differently depending on the
particular cellular membrane where they are anchored, thus
increasing the complexity of RAS signaling.
With respect to NRAS mutant variants, Posch et al.
analyzed the differences in the phosphoproteomic profile of
primary human melanocytes (PHMs) transfected with WT
NRAS and NRAS G12V or Q61L (55). One hundred and
sixty-three phosphosites in 132 proteins were differentially
phosphorylated between NRAS G12V and WT NRAS, with
83 and 80 phosphosites up- and down-regulated, respectively.
PHMs expressing NRAS Q61L showed 202 phosphosites
in 150 proteins differentially regulated compared to PHMs
expressing WT NRAS, with 73 and 129 phosphosites up- and
down-regulated, respectively. Posch et al. also identified 126
proteins and 163 phosphosites 2-fold differentially regulated
between NRAS G12V- and NRAS Q61L-expressing cells
(55), indicating that both NRAS G12V and Q61L have
different phosphoproteomic profiles. Moreover, this work
assessed the enriched canonical pathways regulated by each
NRAS mutant. Whereas, NRAS Q61L-expressing cells showed
an overrepresentation of phosphopeptides related to the MAPK
signaling pathway, NRAS G12V had an enrichment of the “14-
3-3-mediated”- pathway, which is related to the PI3K/AKT
signaling pathway due to the modulation of PI3K signaling
by 14-3-3 protein (55). To confirm these results, changes
in the phosphorylation level of AKT, RPS6, MEK and ERK
were determined. While NRAS G12V-expressing cells showed
an increase in AKT and RPS6 phosphorylation levels, NRAS
Q61L-expressing cells showed an increase in MEK and ERK
phosphorylation levels (55). These data suggest that NRAS G12V
preferentially signals through the PI3K/AKT pathway while
NRAS Q61L activates the MAPK pathway. In addition, Posch
et al. determined kinases differentially expressed between NRAS
G12V and Q61L cells. PHMs expressing NRAS G12V showed
an overrepresentation of phosphosites associated with the PIM2
kinase and other kinases related to the PI3K/AKT signaling
pathway, which correlates with the pathway enrichment reported
in this work, while NRASQ61L-expressing cells showed enriched
CK2α kinase-related sites (55). This in silico prediction was
later confirmed by analyzing clinical samples of NRAS mutant
melanoma. Sixteen out of 18 NRASQ61mutatedmelanomas and
one out of 2 NRAS G12 mutant melanomas showed a positive
expression for CK2α, with higher expression levels in the NRAS
Q61 mutant samples (55). Moreover, the TCGA data set for
skin cutaneous melanoma was analyzed to determine whether
CK2α was differentially expressed between NRAS Q61 and
NRAS G12mutant melanomas. The comparison of CK2αmRNA
levels between both NRAS Q61 and G12 mutant melanomas
showed a higher expression of CK2α in NRAS Q61 mutant
samples (55), confirming thus the in silico prediction. CK2α is
a constitutively active serine/threonine protein kinase involved
in many cellular processes, such as cell growth, proliferation,
and survival (56). Recently, its role in antitumor drug resistance
has been reviewed, pointing to the modulation of PI3K/AKT,
β-catenin and other signaling pathways directly involved in drug
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resistance by CK2α. Moreover, the available CK2α inhibitors
(56) are under evaluation to determine whether this kinase is a
potential target in cancer treatment.
Metabolomics
Brunelli et al. characterized the metabolic profile of the isogenic
NCI-H1299 NSCLC cell line overexpressing WT KRAS or
KRAS G12C, G12D, or G12V (38). The majority of metabolites
identified were common to all three KRAS-mutated lines
(G12C, G12D, and G12V), although these mutants harbored
74, 58, and 48 unique metabolites, respectively, compared to
WT (38). Moreover, the deregulated metabolites between WT
and mutant KRAS variants were classified into biochemical
groups. The two most abundant classes for KRAS G12C, G12D,
and G12V were glycerophospholipids and amino acids. KRAS
G12C and G12D mainly affected phosphatidylcholines (PC)
and phosphatidylinositols (PI), whereas KRAS G12V influenced
PI and phosphatidylserine (38). In addition, the report by
Brunelli et al. provided further insights over the biology of the
deregulated metabolites. KRAS G12C, G12D, and G12V variants
showed an increase of metabolites related to protein biosynthesis,
glutathione, glutamate metabolism and ammonia recycling (38).
Regarding the protein synthesis pathway, all these mutants
displayed greater levels of tryptophan and lower levels of the rest
of the amino acids compared to WT KRAS, with the exception
of the high amount of phenylalanine found in KRAS G12D-
expressing cells (38). Moreover, KRAS G12C, G12D, and G12V
had lower levels of glutamate, glutamine, asparagine and proline,
amino acids interconnected in the glutamate synthase cycle, and
lower levels of NAD+, an essential coenzyme involved in many
cellular metabolic pathways (38). Glutamate and glutamine are
two amino acids involved in glutaminolysis, one of the central
cellular pathways that fuel cancer cells growth and proliferation,
which also support the production of antioxidant molecules such
as glutathione. Considering the low levels of glutamine reported
in this work (38), Brunelli et al. studied glutathione cellular
levels. All analyzed KRAS mutant variants showed low levels of
reduced glutathione (GSH) and pyroglutamic acid, both involved
in glutathione metabolism. However, the GSH level was slightly
higher in KRAS G12C than in KRAS G12D and G12V, but not
different fromWT KRAS (38).
Following on these results (38), the group of Roberta Pastorelli
continued studying the metabolic profile of KRAS G12C, as it
is the most representative KRAS mutation in NSCLC patients.
In this work, the NCI-H1299 NSCLC cell line expressing WT
or KRAS G12C and xenograft tumors generated from this cell
line were analyzed (39). Brunelli et al. identified 26 and 23
deregulatedmetabolites in vitro and in vivo, respectively, between
WT KRAS and KRAS G12C. The enriched pathway analysis of
these deregulated metabolites showed that KRAS G12C alters
the same metabolic pathways in vitro and in vivo, including
pathways involved in protein biosynthesis, ammonia recycling,
and urea cycle (39). Focusing on the deregulated metabolites
whose abundance changed significantly in vitro and in vivo
betweenWT KRAS and KRAS G12C, 11 and 16 metabolites were
significantly altered, respectively. Moreover, in both in vitro and
in vivo models, KRAS G12C decreased the levels of glutamine
and glutamate, two amino acids involved in nitrogen balance
maintenance, supporting the central role of glutaminolysis and
nitrogen anabolism to provide energy for cancer cell growth
and proliferation. This indicates that cells expressing the KRAS
G12C variant use glutaminolysis as a source of energy (39). In
addition, KRAS G12C mutation induced a significant increase
in the levels of carnitine, acetyl-carnitine and butyryl-carnitine,
which are involved in the oxidation of fatty acids (39). This
increase could be associated with the mitochondrial fatty acid
beta oxidation to respond to the increasing energy demand
triggered by KRAS G12C to fuel cell or tumor growth and
proliferation (39). Moreover, the same group previously reported
that KRAS G12C-expressing cells mainly affected PC and PI (38),
showing later a down-regulation of some PC species in vitro but
not in vivo compared to WT KRAS. These changes have been
reported to be an important source of second messengers that
could play a role in theMAPK and PI3K/AKT signaling pathways
that are commonly altered in cancer (57).
In addition to the transcriptomic profile, Charitou et al. also
assessed themetabolic differences betweenWTKRAS- andKRAS
G13D-expressing HKe3 colorectal cancer cells to confirm the
results predicted in their RNAseq analysis (40). The analysis
of 188 endogenous metabolites revealed that 97 of them were
significantly changed between WT KRAS- or KRAS G13D-
expressing cells, showing different metabolic profiles (40). The
metabolic data revealed that KRAS G13D-expressing cells have
an increased abundance of almost all amino acids, results that
are consistent with the pathway analysis of up-regulated genes
(40). In addition, this work showed a decrease in PC levels and
an increase in carnitine and its esters in KRAS G13D-expressing
cells (40). These findings are consistent with those previously
published by Brunelli et al. concerning KRAS G12C (39),
suggesting that these changes are not a codon-specific signature.
The results provided by omics profiling studies indicate that
the differences in biological properties or downstream signaling
pathways activation of distinct RAS proteins mutations are
presumably consequences of their very specific transcriptomic,
proteomic/phosphoproteomic and metabolomic profiles. The
large amount of data provided by such profiles allows the
comparison of different RAS mutant variants to determine their
differences in a particular cancer or to provide important insights
in the response to a specific treatment. Moreover, these studies
identify hits that might be potential targets in therapy, as they
are involved in numerous pathways previously described to be
altered in cancer.
RAS MUTATED VARIANTS AT
NON-CANONICAL CODONS
The most studied mutations in RAS genes are located at the
canonical codons 12, 13, and 61. However, other mutations
at non-canonical codons of RAS, such as 19, 22, 59, 117, or
146, have been described (6, 58–61). Both somatic as well as
germline mutations at these codons have been reported. For
example, NRAS A146T can be found in the leukemic cell lines
NALM6 and ML-216, while HRAS K117N and A146T germline
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mutations have been identified in a small number of patients with
Costello syndrome (62) and KRAS V14I in patients with Noonan
syndrome (60). In addition, point mutations at codon 59 are
commonly identified in the viral forms of HRAS and KRAS (58).
As non-canonical mutations have also been identified in
patients’ samples (59, 60, 62) and thus may be relevant for
oncogenesis, functional and biochemical evaluation of these
mutant protein have been performed in comparison with wild
type RAS or other canonical RAS mutations (6, 59, 60).
Transforming Potential
Feig and Cooper described two different HRAS non-canonical
mutations, V14M and A146V, and assessed their transforming
potential by their ability to form foci (58). Whereas, NIH3T3
fibroblasts expressing HRAS V14M had an indistinguishable foci
formation ability compared to WTHRAS, HRAS A146V showed
an increase in foci formation (58). This work also compared
the transforming potential of WT HRAS and HRAS A59T and
A59I, both of them identified as viral HRAS mutants defective
in their autophoshporylation. HRAS A59T and A59I showed
higher and lower transforming potential, respectively, compared
to WT HRAS (58). The results concerning HRAS A59T are
consistent with those previously published by Fasano et al. (63)
and Lacal et al. (64), where HRAS A59T mutant protein was able
to fully transform NIH3T3 mouse fibroblasts (64) and form foci
compared to WT HRAS (Table 4) (63).
Later, the sequencing of different types of cancers revealed
new mutations at the non-canonical codons 22, 60, 74, and
146 (60, 65). Tsukuda et al. analyzed the transforming potential
and the proliferation rate of KRAS Q22K in vitro and in vivo
(65). NIH3T3 mouse fibroblasts transfected with WT KRAS or
KRAS Q22K were able to form few foci compared to the well-
characterized activating mutation KRAS G12V. However, KRAS
Q22K-expressing fibroblasts showed typical transformed cell
morphology: small, spindle-shaped cells with no tight adherence
(65). Moreover, cells expressing KRAS Q22K were able to grow
under starving, while WT KRAS cells ceased to grow within
10 days under the same experimental conditions. However,
neither WT or mutant KRAS showed tumor formation in vivo
in 15 days (Table 4), whereas fibroblasts expressing KRAS G12V
formed progressive tumors (65). These results indicate that KRAS
Q22K is able to change mouse fibroblasts morphology but its
transforming potential is not sufficient to develop tumors in
vivo. In addition, Tyner et al. transfected A31 fibroblasts and
murine bonemarrow cells withWT or different KRAS andNRAS
mutants (60). Whereas, WT KRAS- or NRAS-expressing cells
exhibited few foci, indicating contact inhibited growth, NRAS
G60E and KRAS T74P and A146T were able to form numerous
foci (Table 4) (60).
Furthermore, Akagi et al. reported another non-canonical
mutation at codon 19 of KRAS (59). To assess its transforming
potential, three different characteristics were measured: cell
morphology, proliferation and saturation density (59). The
transfection of NIH3T3 fibroblasts with plasmids encoding WT
KRAS or KRAS L19F showed that clones expressing this mutant
protein were smaller and more rounded than those expressing
WT KRAS. Moreover, whereas WT KRAS expressing cells ceased TA
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to grow under starved conditions, KRAS L19F clones were able to
grow and had greater density that could be due to their small cell
size and loss of contact inhibition (59). This work also studied
the ability of the mutant KRAS L19F to form tumors in vivo,
reporting that 75% of the KRAS L19F injected clones developed
tumors in contrast to 13% of WT KRAS clones (Table 4) (59).
Therefore, these results indicate that KRAS L19F has a higher
proliferation capacity in vitro and in vivo compared toWTKRAS.
Smith et al. also assessed the transforming potential of the
previously studied non-canonical mutations KRAS L19F and
A146T and two new KRAS mutations, K117N and R164Q (22).
The transduction of NIH3T3 fibroblasts with plasmids expressing
these KRAS mutations and WT KRAS revealed that KRAS
K117N and A146T enabled foci formation, whereas KRAS L19F
only formed isolated foci (Table 4) (22). These findings contrast
with those previously described by Akagi et al. (59) for codon 19,
but in agreement with those published by Tyner et al. (60) for
KRAS A146T.
These observations indicate that, similarly to mutations at
codons 12, 13 and 61, mutations at non-canonical codons of
the different RAS proteins display a diverse phenotype regarding
their transforming potential.
GTP Binding
Feig and Cooper determined the nucleotide binding affinities
of WT HRAS and HRAS V14M and A146V (58). Whereas,
WT HRAS showed affinity of for both GTP and GDP, the
affinity of HRAS V14M and A146V for GTP and GDP were
higher compared to WT HRAS (Figure 1A) (58). Moreover, this
work also assessed the GDP-GTP exchange and the GTPase
activity of HRAS A146V. This mutation showed a fast nucleotide
exchange compared to WT HRAS but the same GTPase activity
(Table 4), indicating that the transforming potential of HRAS
A146V reported in this work was due to an increase in the
speed of nucleotide exchange rather than any alteration in
its GTPase activity (58). Moreover, the nucleotide binding
affinity, nucleotide exchange rate and GTPase activity were
also studied for HRAS A59T and A59I mutant proteins. Both
HRAS A59T and A59I mutations and WT KRAS bound GTP
and GDP. Regarding the nucleotide exchange, whereas HRAS
A59I exhibited nearly the same exchange rate as WT HRAS,
HRAS A59T mutation showed a rate 10-fold greater than
WT HRAS. However, both HRAS A59T and A59I mutant
proteins showed a reduction in their intrinsic GTPase activity
(Table 4) (58). The results concerning HRAS A59T are consistent
with the ones previously published by Lacal and Aaronson
(66), who determined that HRAS A59T showed 3- to 9-
fold greater nucleotide exchange than WT HRAS (66). All
together, these results indicate that the transforming potential
of HRAS A59T is due to a reduction in GTPase activity and
an increase in nucleotide exchange. However, the inability of
HRAS A59I to form foci reported in this work indicates that
a reduction of the GTPase activity is not sufficient to confer
transforming capacity (58), suggesting that changes in the
nucleotide exchange rate are also important at this codon to
acquire transforming capacities.
Akagi et al. studied the ability of RAS non-canonical
mutations to bind GTP (59). KRAS L19F showed elevated
RAS-GTP levels compared to WT KRAS, which was consistent
with the in vitro and in vivo transforming potential of this
KRAS mutant (59). Later on, experiments in HEK 293T/7 cells
transfected with WT or mutants KRAS and NRAS revealed
that NRAS G60E, KRAS T74P, and A146T had increased RAS-
GTP levels compared to WT NRAS and KRAS (Figure 1A,
Table 4) (3). The increase in KRAS T74P-GTP levels could be
explained as the substitution of proline may disrupt the protein
conformation involved in GTP hydrolysis, thus impairing GTP-
GDP exchange (60). In addition, Janakiraman et al. showed
that HEK 293FT cells expressing KRAS Q22K, E31K, K117N,
and A146T were able to bind GTP (Table 4), with KRAS
Q22K mutant variant showing the highest levels and KRAS
E31K levels similar to WT KRAS, establishing the following
hierarchy Q22K >> K117N ≈ A146T >> E31K (62). Later
on, Smith et al. showed that KRAS L19F, K117N, and A146T
were able to bind GTP, but WT KRAS and KRAS R164Q
were not (Figure 1A, Table 4). These results are consistent with
the transforming potential of these mutants reported in this
work (22) and with the previously observed ability of KRAS
L19F and A146T to bind GTP (59, 60, 62). In addition, Stolze
et al. reported that KRAS A18D has a similar GTP-binding to
WT KRAS and control cells, which only express endogenous
KRAS, following EGF stimulation (6). In contrast, KRAS K117N
mutant protein showed an increase in GTP-biding up to 5
to 6-fold compared to control cells (Figure 1A, Table 4) (6),
which is consistent with the data reported by Janakiraman
et al. (62).
Recently, in a 2019 study, Poulin et al. compared the
nucleotide exchange and GTP hydrolysis between WT KRAS
and KRAS A146T (61). The authors reported in this work
that KRAS A146T had ∼12-fold higher GDP dissociation rate
than WT KRAS, a difference that was further increased by
the addition of the GEF protein SOS1. The intrinsic GTP
hydrolysis of KRAS A146T was reduced compared to WT
KRAS (Table 4), while GAP-mediated GTP hydrolysis was only
mildly impaired (61). These results are consistent with those
published previously (22, 60, 62). Therefore, the ability of KRAS
A146T to form foci reported by Tyner et al. and Smith et al.
(22, 60) might be due to an increase in the intrinsic and
GEF-mediated nucleotide exchange rather than a loss of GAP-
mediated exchange (61).
Anchorage-Independent Growth and
Migration
Using colony formation as a measurement of anchorage-
independent growth, Tsukuda et al. have shown that KRAS
Q22K formed only few colonies in soft agar, similar to WT
KRAS (Table 4) (65), indicating that this mutation cannot grow
independent of anchorage, results that are in agreement with
its inability to form tumors in vivo. Later, Akagi et al. reported
that 9.2% of NHI3T3 cells expressing KRAS L19F were able to
form colonies, while fibroblasts expressing WT KRAS failed to
do so (Table 4) (59), consistently with the transforming potential
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assessed in this study. In addition, Stolze et al. reported that
MCF10A breast cancer cells ectopically expressing KRAS A18D
at physiological levels were unable to form colonies in soft
agar (6). However, KRAS K117N expressing cells displayed a
slight increase in colony formation compared to control cells
expressing endogenous KRAS (6). In addition, KRAS A18D- and
K117N-expressing cells showed no increase in their migration
abilities compared to WT KRAS or control cells when they are
expressed at physiological levels (Table 4) (6).
Downstream Pathways Activation and
Outcome
Several studies assessed the activation of RAS downstream
pathways by non-canonical mutations (6, 60, 61). For example,
Tyner et al. studied the activation of the MAPK pathway by
MEK and ERK phosphorylation status (60). Compared to WT
NRAS, HEK 293T/17 cells expressing NRAS G60E showed an
increase in ERK but not in MEK phosphorylation. In the case
of KRAS T74P and A146T, both mutant proteins increased ERK
phosphorylation levels in comparison to WT KRAS, but KRAS
A146T showed higher MEK activation than KRAS T74P and
WT KRAS (Figure 1B, Table 4) (60). In addition, Stolze et al.
reported that MCF10A cells expressing KRAS A18D or K117N at
physiological levels did not show higher phosphorylation levels
of ERK, PDK, and AKT compared to WT KRAS or control
cells expressing endogenous KRAS (Figure 1B, Table 4) (6).
However, either the physiological expression or overexpression
of KRAS K117N increased the activation of RPS6 compared to
WT KRAS and control cells after the addition of EGF (Table 4)
and thus, this mutant enabled the activation of the mTOR
pathway (6). In addition, Poulin et al. analyzed the activation of
the RAS downstream pathways assessing the phosphoproteome
of WT KRAS and KRAS A146T (61). KRAS A146T mutant
protein expressed in the colon increased the phosphorylation
level of ERK1/2 compared to WT KRAS, but less than KRAS
G12D (Table 4) (61). Therefore, KRAS A146T seems to activate
the MAPK pathway less strongly compared to KRAS G12D.
However, the inhibition of this signaling pathway reduced
the proliferation in the colonic epithelium, indicating that the
activation of the MAPK pathway at low levels is sufficient to
increase the proliferation rate in this tissue (61).
In addition to in vitro studies which analyzed RAS mutations
at non-canonical codons, in vivo xenograft models have
also been employed to study the activation of downstream
signaling pathways and related outcomes (61, 62). For
example, Janakiraman et al. showed >95% decrease in
ERK phosphorylation 6h after the inhibition of the MAPK
pathway. Moreover, this inhibition was also associated with a
downregulation of cyclin D1, an increase in p27 expression and
hypophosphorylation of Rb (62).
Poulin et al. studied the phenotype that ensues from
the expression of KRAS A146T in the colonic epithelium,
hematopoietic stem cells and pancreas of genetically engineered
mice (61). In the colonic epithelium, KRAS A146T caused
a moderate hyperplasia and an intermediate proliferation
between KRAS G12D and WT. The expression of KRAS
A146T in hematopoietic stem cells led to a myelodysplastic
syndrome/myeloproliferative neoplasm with a delayed onset
compared to mice expressing KRAS G12D in the same cells, and
these animals died with severe anemia and splenomegaly at an
older age thanKRASG12D-expressingmice (61). However, when
KRAS A146T was expressed in the pancreas, mice showed no
evidence of pancreatic intraepithelial neoplasia at 2 months of
age. Even the induction of acute pancreatitis was not sufficient to
induce pancreatic neoplasia, suggesting that this mutation does
not alter pancreatic homeostasis (61).
Transcriptomics and Proteomics
Differences in overall mRNA and protein expression among RAS
non-canonical codons have been described (22, 61). Smith et al.
performed a hierarchical clustering of transcriptomic data of
WT KRAS, KRAS canonical mutations G12V, G12C, G12D, and
G13D and KRAS non-canonical mutations L19F, K117N, A146T,
and R164Q (22). The analysis revealed two different clusters:
WT KRAS and the codon 12 mutations clustered in one group
(“cluster one”) while the codon 13 and non-canonical mutations
clustered in a second group (“cluster two”), indicating that non-
canonical mutations displayed similar gene expression profile to
KRAS G13D. Despite previous results of this study showing that
KRAS R164Q had a similar transforming potential to WT KRAS
(22), this mutation was grouped in the “cluster two,” suggesting
an attenuated transforming potential. In addition, KRAS L19F
and R164Q formed a transcriptomic subcluster within the
“cluster two,” suggesting that these two mutations are different
from KRAS G13D, K117N, and A146T (22). Furthermore,
Smith et al. analyzed the expression of genes involved in signal
transduction, cytoskeleton remodeling and cell adhesion (22).
Despite the few changes in gene expression induced by KRAS
R164Q, there were examples of genes whose expression was
induced by all mutants, such as the protein tyrosine phosphatase
PTPRE and the RHOGTPase-activating proteinARHGAG6 (22).
Moreover, genes induced or repressed by all of themutants except
KRAS R164Q were identified, including the MAPK phosphatases
DUSP4 and DUSP6, the RHO guanine-exchange factor NGEF,
the cell adhesion molecule CEACAM1 and the plasminogen
activator inhibitor SERPINB2. Interestingly, “cluster one” but not
“cluster two” KRAS mutants differentially expressed some genes,
for example VEGFA, PAK3, or PIM1; and “cluster two” but not
“cluster one” mutants showed a different expression of IGF1R
and CREB1 among other genes. Additional genes, such as E2F2,
SLC2A1, or JUN, were differentially regulated by all the analyzed
mutants (22).
Poulin et al. studied the proteome and phosphoproteome of
colon, pancreas and spleen from mice expressing WT KRAS
or the mutant proteins KRAS G12D and A146T (61). The
data derived from each tissue revealed that the two mutant
variants and WT KRAS clustered separately. The collective
analysis of all data showed that samples from the same tissue
cluster together regardless of the KRAS mutation and samples
expressing KRAS A146T tended to cluster closer to the ones
expressing WT KRAS (61), suggesting that WT KRAS and KRAS
A146T display similar proteomic and phosphoproteomic profiles
in these tissues. Moreover, the same authors uncovered the
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enriched biological pathways in KRAS G12D or A146T using
the dataset of each tissue analyzed (61). In the colon dataset,
KRAS G12D and A146T differentially regulated the majority of
the enriched pathways, such as the calcium signaling pathway.
Similar to the colon-associated data, the majority of pathways
enriched in the pancreas dataset were discordantly regulated by
both mutations. Interestingly, whereas the nitrogen metabolism
pathway was up-regulated by KRAS G12D and A146T in colon,
the same pathway was down-regulated in the pancreas. In the
spleen dataset, KRAS G12D and A146T showed no pathways
differentially regulated by the two mutants compared to WT
KRAS (61). Conclusively, KRAS G12D and A146T differentially
regulate downstream signaling pathways, depending also on the
tissue where these mutant proteins are expressed.
All together, these results suggest that, similarly to mutations
at codons 12, 13, and 61, mutations at non-canonical codons
of RAS proteins display different biological manifestations
that relate to their transforming potential and GTP binding.
Moreover, these mutations activate differently RAS downstream
signaling pathways and alter genes and proteins expression
compared to theWT protein. However, non-canonical mutations
are less studied compared to mutations at codons 12, 13, and 61,
despite the fact that they have been described in patients’ samples.
Therefore, it is of an immense interest to continue studying
their biological characteristics in vitro and in vivo to uncover
more over the properties of those uncommon variants and their
relevance to RAS-related oncogenesis.
RAS PROTEINS MUTATIONS AFFECT
TREATMENT RESPONSES
KRAS is the most frequently mutated RAS protein in cancer
(5) and therefore the most studied in clinical trials for different
therapy regimen 1. The association between treatment responses
and survival in patients carrying KRAS mutant variants has been
studied since the late 1990s (67). For example, Keohavong et al.
reported that lung cancer patients carrying the KRAS G12V or
G12R mutations had a shorter overall survival (OS) compared
to those with WT KRAS tumors, while KRAS G12D-carrying
patients showed longer survival (67). Regarding treatment
response, Petrelli et al. reported in ameta-analysis of 12 colorectal
cancer clinical trials that patients carrying WT KRAS had a
better response rate (RR) to chemotherapy plus bevacizumab
than those harboring KRAS-mutated tumors (68). Of particular
importance, Allegra et al. reported in their retrospective study
that colorectal cancer (CRC) patients carrying KRAS mutant
variants do not benefit from the anti-EGFR antibodies cetuximab
and panitumumab (69). However, it has also been demonstrated
that about 10% of the patients with KRAS-mutated tumors can
respond to anti-EGFR therapy and about 15% have long-term
disease stabilization (70). This subchapter discusses in detail
the relation between KRAS mutant variants and survival and
treatment response of patients with various cancer types that are
particularly prone to carry KRAS mutations.
1https://clinicaltrials.gov
Colorectal Cancer
Approximately 40% of CRC cases harbor KRAS mutations
at codons 12, 13, and 61, resulting mainly in the KRAS
G12D, G12V, and G13D variants (2, 5). Almost already 10
years ago, De Rock et al. analyzed whether the presence of
the KRAS G13D mutant variant is associated with treatment
response or survival of CRC patients (70). As KRAS G13D has
been reported to exhibit weaker transforming potential than
KRAS codon 12 mutant variants (6, 22, 25), De Rock et al.
hypothesized that patients harboring KRAS G13D mutation
might have a better outcome after cetuximab treatment compared
to patients carrying other KRAS mutant variants. To confirm
this hypothesis, 579 patients with varying KRAS status who had
chemotherapy-refractory metastatic colorectal cancer (mCRC)
were divided into two different treatment lines: cetuximab only
and cetuximab plus chemotherapy (70). Compared to other
KRAS mutant variants, patients carrying KRAS G13D mutant
variant who received cetuximab treatment, either alone or in
combination with chemotherapy, had longer OS (median 7.6
months vs. median, 5.7 months, HR, 0.50) and progression-free
survival (PFS) (median 4.0 months vs. median, 1.9 months, HR,
0.51). However, no significant differences in OS or PFS were
identified in KRASG13D patients compared to those carrying the
WT KRAS (70). Similarly, patients with KRAS G13D-expressing
tumors receiving the combination treatment of cetuximab plus
chemotherapy showed longer OS and PFS than patients carrying
other KRAS mutant variants (OS: median, 10.6 months vs. 7.4
months, HR, 0.46; PFS: median, 4.1 months vs. 2.8 months,
HR, 0.49). No differences between KRAS G13D and WT KRAS
regarding OS and PFS were identified, results also reported
in the “cetuximab only” group (70). These results confirmed
that patients carrying KRAS G13D benefited from cetuximab
treatment compared to those carrying other KRAS mutant
variants, which may be explained by the weak transforming
potential showed in vitro (70). This work also compared the
RRs of KRAS G13D patients in the different treatment groups
(70). Patients carrying KRAS G13D mutant variant receiving the
combination of cetuximab plus chemotherapy showed higher
but not statistically significant RR compared to patients with
other KRAS mutations. However, patients carrying WT KRAS in
the cetuximab plus chemotherapy treatment arm showed higher
RR than those with tumors expressing KRAS G13D, but this
difference is not statistically significant when WT KRAS patients
are compared to KRAS G13D patients receiving cetuximab only
(70). In addition, De Rock et al. studied the in vivo response
to cetuximab (70). Cetuximab inhibited the growth of tumors
harboringWTKRAS or KRAS G13D, showing a similar response
to the treatment; however, the treatment did not affect the growth
of KRAS G12V-expressing tumors (70), suggesting that KRAS
codon 12 mutant variants are resistant to cetuximab.
Later, Tepjar et al. combined the data of 1,378 mCRC patients
included in the previous clinical trials (71). In this work, patients
carrying the KRAS G13D mutant variant had additional benefit
from chemotherapy plus cetuximab than from chemotherapy
alone. These patients showed higher PFS (median 7.4 vs. 6.0
months; HR, 0.47) and tumor response (median 40.5 vs. 22.0%
months; OR, 3.38), but not OS (median 15.4 vs. 14.7 months; HR,
Frontiers in Oncology | www.frontiersin.org 17 October 2019 | Volume 9 | Article 1088
Muñoz-Maldonado et al. Comparison of RAS Mutations in Cancer
0.89), when cetuximab was added to the chemotherapy regimen.
These results could partially be explained by the worse prognosis
of KRAS G13D patients in the control arm (71). Opposite
to KRAS G13D, patients carrying the KRAS G12V mutant
variant receiving chemotherapy plus cetuximab showed worse
PFS than those receiving chemotherapy only (71). When only
the chemotherapy plus cetuximab treatment armwas considered,
patients carrying G13D or G12V mutant variants showed a
similar OS, which was markedly lower than those patients with
WT KRAS tumors (71). Within the chemotherapy only arm,
patients with KRAS G13D mutant tumors tended to have worse,
but not statistically significant, PFS and OS compared to those
harboring tumors with other KRAS mutant variants (PFS: HR,
1.49; OS: HR, 1.25). However, patients with KRAS G12V tumors
did not showed worse PFS or OS compared to other KRAS
mutant tumors (PFS: HR, 0.77; OS: HR, 1) (71).
Similarly, Fiala et al. studied KRAS mutations at codons
12 and 13 of mCRC patients treated with the anti-angiogenic
antibody bevacizumab who previously have received different
chemotherapeutic regimen (72). Patients carrying mutant
variants at codons 12 or 13 had shorter OS and PFS than those
with WT KRAS (72). When each KRAS mutant variant was
analyzed independently, patients carrying KRAS G12V or G12A
had shorter PFS and OS compared to WT KRAS patients (PFS:
HR= 2.18; OS: HR= 2.58) (72).
The impact of KRAS mutant variants have been analyzed not
only in relation to chemotherapy, but also regarding surgery as a
treatment strategy (73, 74). Mangonis et al. studied the outcome
of CRC patients carrying KRAS mutations after curative intent
liver resection due to liver metastasis (73). Patients carrying
KRAS mutant variants at codon 12 (G12V, G12D, G12C, G12S,
and G12A) or KRAS G13D had no significant differences in
5-year recurrence-free survival (RFS) compared to WT KRAS
patients (p = 0.57). Moreover, none of the aforementioned
mutant variants were associated with worse RFS than WT KRAS
(73). In addition, patients carrying any KRAS codon 12 mutant
variant had worse 5-year OS compared to WT KRAS patients
(HR, 1.7), while KRAS G13D patients had no differences in OS
compared to those carrying WT KRAS (HR, 1.47) (73). When
each KRAS mutant variant was analyzed independently, KRAS
G12V and G12S were associated with 2- to 3-fold increase risk
for long-term death compared toWTKRAS patients. In addition,
patients carrying KRAS G12V, G12S, and G12C had a higher
risk of death after recurrence compared to those harboring WT
KRAS who recurred (73). Recently, Hayama et al. analyzed 200
CRC patients who underwent curative resection (74). Analysis
of relapse-free survival revealed that a small proportion of
patients carrying KRAS mutant variants G12D, G12V, G12C,
G12A, G12S, or G13D reached the 3-year relapse-free survival
endpoint compared to those carrying WT KRAS (69.7 vs. 82.1%,
respectively; p = 0.01). Moreover, patients carrying KRAS G12V
or G12C had a higher risk of long-term recurrence than those
withWT KRAS tumors or KRAS G12A, G12D, or G12S-mutated
CRC (74).
Independently of the type of treatment (chemotherapy or
surgery), CRC patients carrying KRAS G13D mutant variant
seem to show no significant differences in PFS, OS or RFS as
compared to WT KRAS across these various studies. However,
patients harboring KRAS codon 12 mutant tumors generally had
worse PFS, OS, RFS and RR compared to patients with WT
KRAS tumors. This could be potentially explained by the fact that
KRAS codon 12 mutant variants, especially the G12V and G12D
mutations, have been reported to have a very high transforming
potential and a low GTP intrinsic and GAP-mediated GTP
hydrolysis (6, 22, 25). Importantly, this also correlates with
the in vivo animal models findings reported by De Rock et al.
regarding KRAS G12V and its resistance to cetuximab (70) and
with preclinical results by Leiser et al. on KRAS G12V, G12D,
and G13D mutant variants conferring resistance to two different
MET inhibitors (75).
Non-small Cell Lung Cancer (NSCLC)
KRAS mutations, mainly KRAS G12C, G12D, and G12V,
are observed in 20–30% of NSCLC patients, predominantly
in patients with adenocarcinomas (2, 76). Subsequently, the
association between KRAS mutant variants and treatment
survival in NSCLC has also been extensively studied (23, 76, 77).
For example, Ihle et al. reported that patients with refractory
NSCLC carrying KRAS G12C or G12V mutant variants showed
a statistically significant decrease in PFS (median survival =
1.84 months; p = 0.046) compared to other KRAS mutant
variants (G12A and G12D) (median survival = 3.35 months)
or WT KRAS (median survival = 1.95 months) (23). This
association was more pronounced in patients receiving sorafenib
whereas no statistically significant association was identified
between patients harboring KRAS G12C or G12V mutations and
PFS in either erlotinib or bexarotene plus erlotinib treatment
groups (23). Later on, Mellema et al. analyzed whether there
was an association between KRAS codon 12 mutant variants
and OS, PFS and RR in 464 advanced NSCLC patients
who received platinum-based chemotherapy as a first-line
treatment (76) Patients in this study were treated with different
agents (pemetrexed, gemcitabine, taxane or bevacizumab) in
addition to the previously administrated platinum treatment
(76). Interestingly, patients carrying KRAS G12V mutant variant
showed a higher RR when treated with taxanes than those
harboring the same mutant variant but treated with pemetrexed
or gemcitabine. However, KRAS G12V patients in the taxanes
group had longer, but not statistically significant, PFS and OS
compared to patients carrying the same mutant variant but
treated with pemetrexed or gemcitabine. Moreover, patients
carrying KRAS G12C or G12D mutant variants had similar RR,
PFS and OS within all treatment groups (76). In addition, this
work assessed the PFS and OS among KRAS G12C, G12V, and
G12D mutant variants independently of the received treatment,
showing no differences (PFS: median 4.9, 4.8, and 4.3 months
for G12C, G12V, and G12D, respectively (p = 0.45); OS: median
10.4, 8.0, and 8.3months for G12C, G12V, andG12D, respectively
(p= 0.46) (76).
Interestingly, Renaud et al. also analyzed KRAS-mutated
patients with NSCLC who received platinum-based
chemotherapy as first-line treatment, with similar treatment
arms: pemetrexed, vinorelbine, gemcitabine, taxane, or
bevacizumab (77). Amino acid substitutions in KRAS did
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not affect patients’ OS even when differences in treatment were
considered (77). When assessing the time to progression (TTP),
treatments with vinorelbine and taxane were associated with
a better TTP (HR, 0.76 and 0.32, respectively) compared to
gemcitabine and pemetrexed treatment arms. However, KRAS
mutational status was not a significant predictor of TTP, despite
the fact that patients carrying KRAS G12D or G12V mutant
variants tended to have a better, but not statistically significant,
TTP compared to those carrying KRAS G12C. This tendency
was also observed in patients carrying KRAS G13D mutant
variant when treated with taxane. Interestingly, all KRAS mutant
variants identified in this study were associated with worse TTP
when treated with bevacizumab compared to other treatment
regimen (77).
To summarize, in the case of NSCLC, contradictory results
addressing the impact of KRAS different mutations in clinical
settings are being reported. While Ihle et al. and Mellema et al.
reported that patients carrying KRAS G12V mutant variant
showed longer OS and PFS when treated with taxanes compared
to other treatment regimen (23, 76), Renaud et al. reported
no differences among the codon 12 amino acid substitution
considering the various treatment arms, including taxanes (77).
Moreover, this work showed that patients with KRAS G12D
or G12V-expressing tumors tended to have better TTP than
those with KRAS G12C tumors (77), which contrasts with the
higher PFS and OS reported by Mellema et al. for KRAS G12C
patients (76). Additional studies would thus be needed to allow
for consistent conclusions and potential clinical implementation
of such findings.
Pancreatic Ductal Adenocarcinoma
Pancreatic adenocarcinoma is considered one of the most
aggressive forms of cancer. KRAS mutations are carried
approximately by 90% of the patients and can be detected at
both early and chronic stage of the disease (5). Among all the
possible KRAS mutant variants, the most frequently observed in
the pancreatic ductal adenocarcinoma (PDAC) are KRAS G12D
and G12V (2).
As previous studies in colorectal and lung cancer have
demonstrated that KRAS status influences patients prognosis
(23, 71), Bournet et al. studied whether KRAS codon mutant
variants were associated with the OS in 219 patients with
metastatic or locally advanced PDAC (78). This work reported
no differences in OS between patients carrying WT KRAS or
codon 12 mutations (KRAS G12D, G12V, and G12R). However,
KRAS G12D patients showed a decreased OS compared to KRAS
G12V or G12R patients (78). These results are in agreement
with the previously published data by Boeck et al. who reported
median OS of 5.3 months for patients carrying KRAS G12D,
6.6 months for those with the KRAS G12V mutation and
7.7 months for patients with tumors harboring the G12R
KRAS mutation (79). Moreover, Bournet et al. showed that
among all the 162 patients who received chemotherapy, those
carrying the KRAS G12D mutant variant had a worse prognosis
compared to those with KRAS G12V or G12R. However, patients
carrying KRAS codon 12 mutant variant in the chemotherapy
treatment subgroup showed no difference in OS compared to
WT KRAS patients. Similar results were also reported in a
subgroup of 119 patients who received gemcitabine as first-line
treatment (78).
Collectively, data summarized in this chapter suggest that
CRC patients carrying the KRAS G13D mutant variant show
a similar treatment response as those carrying WT KRAS and,
thus, will benefit from anti-EGFR therapy. Interestingly, KRAS
codon 12 mutants showed different outcome results depending
on the cancer type and treatment employed. These results
are reflected in KRAS G12V patients, who showed worse PFS
when treated with cetuximab but an increase in this endpoint
with taxanes treatment. However, of course, such generalization
of the results should be taken into consideration only very
carefully due to the possible differences in basic patients’
characteristics, the sample size and the treatment regimen in
each study.
FINAL REMARKS
In these emerging times of personalized medicine, it is
highly anticipated that detailed knowledge of cancer genomic
landscapes may improve treatments, resulting ultimately in
a significant increase of patients’ survival. The members
of the RAS subfamily of GTPases, which includes KRAS,
HRAS, and NRAS, are frequently mutated in cancer. KRAS
is often altered in pancreatic carcinoma, colorectal tumors
and lung malignancies and HRAS mutations are common
in dermatological malignancies and head and neck cancers
whereas NRAS alterations in melanomas and in hematopoietic
malignancies. Despite the differences in mutations rates at
each codon, the three RAS proteins are usually mutated at
the canonical codons 12, 13, and 61. However, other mutant
variants have been described at non-canonical codons such
as 19, 59, 117, and 146, illustrating the complexity that is
affiliated with thes oncogenes. As canonical codons are located
in the homologous amino-acid region, shared by all RAS
proteins, it could be postulated that their effect on the protein
function is equivalent. However, various experimental lines
of evidence summarized in this review have demonstrated
that not all RAS mutant variants display the same biological
and biochemical properties, suggesting that tumors harboring
different RAS mutations may behave differently according
to the expressed RAS mutant variant. Therefore, detailed
knowledge about the biological and biochemical properties
of each RAS mutant variant in vitro and in vivo seems to
be essential to help understand the biology of the particular
treatment and possibly predict patients’ treatment response
and survival.
At the same time, the vast majority of preclinical as
well as clinical studies are mostly focused on RAS canonical
mutations. However, rare RAS mutant variants seem to display
similar differences in their biological properties and downstream
signaling activation and, thus, their more extensive studying
could help to better understand the behavior of RAS-expressing
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tumors. Screening and additional biologic characterization of
these non-canonical RAS mutations should also be considered in
clinical practice as mutational analyses of codons 12, 13, and 61
only may misclassify patients that could benefit from particular
anti-cancer therapies.
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